NCT02014636View on ClinicalTrials.gov

Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 27, 2013

Primary Completion Date

February 27, 2019

Study Completion Date

February 27, 2019

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Pazopanib

Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg

DRUG

MK-3475

MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.

Trial Locations (6)

10065

Novartis Investigative Site, New York

37203

Novartis Investigative Site, Nashville

02115

Novartis Investigative Site, Boston

02215

Novartis Investigative Site, Boston

M20 4BX

Novartis Investigative Site, Manchester

W1G 6AD

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY